| HOME >> BIOLOGY >> TECHNOLOGY |
In this BioPharm
International exclusive
interview,SiBionos
founder relates the
science and
manufacture of his
companys innovative
cancer therapy.
Dr.Zhaohui Peng is the chairman,chief executive officer, and founder of Shenzhen SiBiono GeneTech Co., Ltd.,
Langshen Road, Shenzhen Hi-Tech Industrial Park, Shenzhen, China,
0755.2696.8818,
fax: 0755.2696.8808,
sbn@sibiono.com;www.sibiono.com
In October 2003, Shenzhen SiBiono
GeneTech made history by becoming the
first company approved to market a gene
therapy medication. Chinas State Food
and Drug Administration (SFDA) approved
Gendicine for treatment of head and neck
squamous cell carcinoma (HNSCC). SiBiono
believes that continued clinical trials will
prove Gendicine to be effective as a widespectrum
anticancer agent.
In March, BioPharm International interviewed Dr. Zhaohui Peng, SiBiono's founder, chairman, and CEO, to learn more about the science behind gene therapy, the clinical experience with Gendicine, and the processes involved in manufacturing this ground-breaking new therapy. In addition to a distinguished academic career, Dr. Peng served as director of a research institute at The First Medical University in Guangzhou and as a visiting professor at both the University of Chiba in Japan and the University of California. He also conducted research at two US biotech companies. Dr. Peng has devoted more than ten years to gene therapy research, development, and commercialization.
GENE THERAPY BASICS
BPI: You have used the term adenoviral
vector +p53 tumor suppressor-gene delivery
system. Will you briefly describe the science
'"/>
Source: